Overweight Or Obesity And Type 2 Diabetes clinical trials

Explore recruiting overweight or obesity and type 2 diabetes clinical trials.

Recruiting overweight or obesity and type 2 diabetes studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Overweight Or Obesity And Type 2 Diabetes trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and safety of NNC0487-0111 s.c. once-weekly compared to semaglutide s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 8)

Germany, Croatia, Portugal, Hungary, Bulgaria, Romania +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)

Italy, Croatia, Hungary, Slovakia, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes

Czechia, Romania, Croatia, Slovakia, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

EVALUATING THE EFFICACY AND SAFETY OF MET097, A FULLY- BIASED ULTRA LONG-ACTING GLP-1 RA IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES: A PHASE 3, MULTI-CENTER RANDOMIZED PLACEBO-CONTROLLED TRIAL (VESPER-5)

Czechia, Bulgaria, Slovakia, Spain, Hungary, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity and type 2 diabetes

Ireland, Hungary, Austria, Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus

Netherlands, Czechia, Denmark, Spain, Poland, Germany +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Overweight Or Obesity And Type 2 Diabetes trials by city

Overweight Or Obesity And Type 2 Diabetes in Toronto Overweight Or Obesity And Type 2 Diabetes in Vancouver Overweight Or Obesity And Type 2 Diabetes in Montreal Overweight Or Obesity And Type 2 Diabetes in Calgary Overweight Or Obesity And Type 2 Diabetes in Edmonton Overweight Or Obesity And Type 2 Diabetes in Ottawa Overweight Or Obesity And Type 2 Diabetes in Winnipeg Overweight Or Obesity And Type 2 Diabetes in Quebec City Overweight Or Obesity And Type 2 Diabetes in Hamilton Overweight Or Obesity And Type 2 Diabetes in Kitchener Overweight Or Obesity And Type 2 Diabetes in London Overweight Or Obesity And Type 2 Diabetes in Halifax Overweight Or Obesity And Type 2 Diabetes in New York Overweight Or Obesity And Type 2 Diabetes in Los Angeles Overweight Or Obesity And Type 2 Diabetes in Chicago Overweight Or Obesity And Type 2 Diabetes in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease